Alimentary Pharmacology & Therapeutics · 2003 · 101 citations · 36 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyGastroenterologyPharmacogeneticsEsophageal DiseasesGastroesophageal Reflux DiseaseGastrointestinal PathophysiologyGastrointestinal PharmacologyCyp2c19 Drug MetabolismCyp2c19 GenotypeCyp2c19 PharmacogeneticsGastroesophageal Reflux Disease PharmacotherapyHelicobacter Pylori InfectionPharmacologic Therapy For GerdReflux Esophagitis
BACKGROUND: The acid suppressive effect of lansoprazole is influenced by the P450 2C19 (CYP2C19) polymorphism. AIM: To investigate whether the CYP2C19 genotype is related to the healing of erosive reflux oesophagitis during treatment with lansoprazole. METHODS: Eighty-eight Japanese patients with erosive reflux oesophagitis were treated with a daily oral dose of 30 mg lansoprazole for 8 weeks. The CYP2C19 genotype, Helicobacter pylori infection status and serum pepsinogen I/II ratio were assessed before treatment. At 4 and 8 weeks, the healing of erosive reflux oesophagitis was evaluated endoscopically. RESULTS: The healing rates were 57.1%, 69.2% and 72.7% at 4 weeks and 77.4%, 95.0% and 100% at 8 weeks in homozygous extensive metabolizers, heterozygous extensive metabolizers and poor metabolizers, respectively. At 8 weeks, the healing rate of erosive reflux oesophagitis was significantly lower in homozygous extensive metabolizers than in the other two groups (P < 0.05). The H. pylori status and serum pepsinogen I/II ratio had less influence than CYP2C19 polymorphism on the healing rate of erosive reflux oesophagitis. CONCLUSIONS: The therapeutic effect of lansoprazole on erosive reflux oesophagitis is influenced by the CYP2C19 genotype status. Therefore, a test of CYP2C19 genotype may be useful for the medical treatment of reflux oesophagitis with lansoprazole.
36
The endoscopic assessment of esophagitis: A progress report on observer agreement
David Armstrong, J R Bennett, A.L. Blum et al. · Gastroenterology · 1996 · 1.1K citations